Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial-Reference-Cited by-同舟云学术

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Published:2021-01 Issue: Volume:47 Page:102641
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Palace Jacqueline,Wingerchuk Dean M.^ORCID,Fujihara Kazuo,Berthele Achim,Oreja-Guevara Celia,Kim Ho Jin,Nakashima Ichiro,Levy Michael,Terzi Murat,Totolyan Natalia,Viswanathan Shanthi,Wang Kai-Chen,Pace Amy^ORCID,Yountz Marcus,Miller Larisa,Armstrong Róisín,Pittock Sean

Funder

Alexion Pharmaceuticals

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference31 articles.

1. Impact of rituximab on relapse rate and disability in neuromyelitis optica;Bedi;Mult. Scler.,2011

2. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review;Chamberlain;J. Neurol. Epub.,2019

3. An open label study of the effects of rituximab in neuromyelitis optica;Cree;Neurology,2005

4. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis;Damato;JAMA Neurol.,2016

5. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica;Duan;J. Neuroinflamm.,2018

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New treatment options for Neuromyelitis optica spectrum disorders (NMOSD);Neurologie pro praxi;2024-06-20

2. Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2024-05

3. Predicting time to serologic diagnosis of AQP4+ NMOSD based on clinical factors and social determinants of health;Multiple Sclerosis and Related Disorders;2024-03

4. Updates in NMOSD and MOGAD Diagnosis and Treatment;Neurologic Clinics;2024-02

5. Neuromyelitis optica spectrum disorders and complement system: issues of pathogenesis and therapeutic options;Neurology, Neuropsychiatry, Psychosomatics;2023-12-17